申请人:Astellas Pharma Inc.
公开号:US20150203505A1
公开(公告)日:2015-07-23
[Problem]
To provided a compound which is useful as an MT1 and/or MT2 receptor agonist.
[Means for Solution]
The present inventors have conducted studies on MT1 and/or MT2 receptor agonists, and have found that an indole carboxamide compound has an MT1 and/or MT2 receptor agonistic action, thereby completing the present invention. The indole carboxamide compound of the present invention has the MT1 and/or MT2 receptor agonistic action as well as a low CNS penetration, and therefore, it can be used as an agent for preventing and/or treating urological diseases; in one embodiment, lower urinary tract symptoms; in another embodiment, urine storage symptom, in another embodiment, urinary incontinence; in a still another embodiment, stress urinary incontinence; and the like.
[问题] 提供一种作为MT1和/或MT2受体激动剂有用的化合物。 [解决方法] 现在的发明者对MT1和/或MT2受体激动剂进行了研究,并发现一种吲哚羧酰胺化合物具有MT1和/或MT2受体激动作用,从而完成了本发明。 本发明的吲哚羧酰胺化合物具有MT1和/或MT2受体激动作用以及低CNS穿透性,因此,它可以用作预防和/或治疗泌尿系统疾病的药物; 在一种实施例中,是下尿路症状; 在另一种实施例中,是尿液储存症状; 在另一种实施例中,是尿失禁; 在仍另一种实施例中,是压力性尿失禁; 等等。